Treatment resistance in psychiatry: state of the art and new directions.
Journal
Molecular psychiatry
ISSN: 1476-5578
Titre abrégé: Mol Psychiatry
Pays: England
ID NLM: 9607835
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
18
02
2021
accepted:
10
06
2021
revised:
26
05
2021
pubmed:
15
7
2021
medline:
6
4
2022
entrez:
14
7
2021
Statut:
ppublish
Résumé
Treatment resistance affects 20-60% of patients with psychiatric disorders; and is associated with increased healthcare burden and costs up to ten-fold higher relative to patients in general. Whilst there has been a recent increase in the proportion of psychiatric research focussing on treatment resistance (R
Identifiants
pubmed: 34257409
doi: 10.1038/s41380-021-01200-3
pii: 10.1038/s41380-021-01200-3
pmc: PMC8960394
mid: EMS127613
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
58-72Subventions
Organisme : Medical Research Council
ID : MC_U120097115
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_A656_5QD30_2135
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 094849/Z/10/Z
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N027078/1
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2021. The Author(s).
Références
Mead BT, Ellsworth RB, Grimmett JO. The treatment of drug-resistive chronic-schizophrenics. J Nerv Ment Dis. 1958;127:351–8.
pubmed: 13599041
doi: 10.1097/00005053-195810000-00006
Haskovec L, Rysanek K. The action of reserpine in imipramine-resistant depressive patients. Psychopharmacologia. 1967;11:18–30.
pubmed: 4876300
doi: 10.1007/BF00401505
Davidson J, McLeod M, Law-Yone B, Linnoila M. A comparison of electroconvulsive therapy and combined phenelzine-amitriptyline in refractory depression. Arch Gen Psychiatry. 1978;35:639–42.
pubmed: 727903
doi: 10.1001/archpsyc.1978.01770290121011
Gitlin M. Treatment-resistant bipolar disorder. Mol Psychiatry. 2006;11:227–40.
pubmed: 16432528
doi: 10.1038/sj.mp.4001793
Bloch MH, Storch EA. Assessment and management of treatment-refractory obsessive-compulsive disorder in children. J Am Acad Child Adolesc Psychiatry. 2015;54:251–62.
pubmed: 25791142
pmcid: 4460245
doi: 10.1016/j.jaac.2015.01.011
Canuso CM, Singh JB, Fedgchin M, Alphs L, Lane R, Lim P, et al. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry. 2018;175:620–30.
pubmed: 29656663
doi: 10.1176/appi.ajp.2018.17060720
Singh JB, Fedgchin M, Daly EJ, De Boer P, Cooper K, Lim P, et al. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry. 2016;173:816–26.
pubmed: 27056608
doi: 10.1176/appi.ajp.2016.16010037
ClinicalTrials.gov. Effect of Lu AF35700 in patients with treatment-resistant schizophrenia (DayBreak) [ClinicalTrials.gov Identifier: NCT02717195]. 2016.
Hamburg MA, Collins FS. The path to personalized medicine. N. Engl J Med. 2010;363:301–4.
pubmed: 20551152
doi: 10.1056/NEJMp1006304
Freud S. A General Introduction to Psychoanalysis (Williams & Wilkins, 1920).
Jones MS. Coma resistance and adrenalæmia in the insulin treatment of schizophrenia: (Section of Psychiatry). Proc R Soc Med. 1939;32:958–68.
pubmed: 20916387
pmcid: 1997637
Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789–96.
pubmed: 3046553
doi: 10.1001/archpsyc.1988.01800330013001
Leucht S, Samara M, Heres S, Patel MX, Woods SW, Davis JM. Dose equivalents for second-generation antipsychotics: the minimum effective dose method. Schizophr. Bull. 2014;40:314–26.
pubmed: 24493852
pmcid: 3932104
doi: 10.1093/schbul/sbu001
Brissos S, Veguilla MR, Taylor D, Balanza-Martinez V. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol. 2014;4:198–219.
pubmed: 25360245
pmcid: 4212490
doi: 10.1177/2045125314540297
Citrome L. New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia. Expert Rev Neurother. 2013;13:767–83.
pubmed: 23898849
doi: 10.1586/14737175.2013.811984
Guo X, McCutcheon RA, Pillinger T, Mizuno Y, Natesan S, Brown K, et al. The magnitude and heterogeneity of antidepressant response in depression: a meta-analysis of over 45,000 patients. J Affect Disord. 2020;276:991–1000.
pubmed: 32750615
doi: 10.1016/j.jad.2020.07.102
Samara MT, Dold M, Gianatsi M, Nikolakopoulou A, Helfer B, Salanti G, et al. Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis. JAMA Psychiatry. 2016;73:199–210.
pubmed: 26842482
doi: 10.1001/jamapsychiatry.2015.2955
Mizuno Y, McCutcheon RA, Brugger SP, Howes OD. Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: a meta-analysis. Neuropsychopharmacology. 2020;45:622–31.
pubmed: 31766049
doi: 10.1038/s41386-019-0577-3
Rodriguez P, Holowka DW, Marx BP. Assessment of posttraumatic stress disorder-related functional impairment: a review. J Rehabil Res Dev. 2012;49:649–65.
pubmed: 23015577
doi: 10.1682/JRRD.2011.09.0162
Soyka M, Mutschler J. Treatment-refractory substance use disorder: focus on alcohol, opioids, and cocaine. Prog Neuro-Psychopharmacol Biol Psychiatry. 2016;70:148–61.
doi: 10.1016/j.pnpbp.2015.11.003
Sanderson WC, Bruce TJ. Causes and management of treatment-resistant panic disorder and agoraphobia: a survey of expert therapists. Cogn Behav Pract. 2007;14:26–35.
doi: 10.1016/j.cbpra.2006.04.020
Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJM, Birnbaum ML, et al. Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017;174:216–29.
pubmed: 27919182
doi: 10.1176/appi.ajp.2016.16050503
McCutcheon R, Beck K, Bloomfield MAP, Marques TR, Rogdaki M, Howes OD. Treatment resistant or resistant to treatment? Antipsychotic plasma levels in patients with poorly controlled psychotic symptoms. J Psychopharmacol. 2015;29:892–7.
pubmed: 25788157
pmcid: 4902121
doi: 10.1177/0269881115576688
Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand. 2002;105:164–72.
pubmed: 11939969
doi: 10.1034/j.1600-0447.2002.1r084.x
Demjaha A, Lappin JM, Stahl D, Patel MX, MacCabe JH, Howes OD, et al. Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. Psychol Med. 2017;47:1981–9.
pubmed: 28395674
doi: 10.1017/S0033291717000435
Lally J, Ajnakina O, Di Forti M, Trotta A, Demjaha A, Kolliakou A, et al. Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. Psychol Med. 2016;46:3231–40.
pubmed: 27605254
doi: 10.1017/S0033291716002014
Rutherford BR, Wager TD, Roose SP. Expectancy and the treatment of depression: a review of experimental methodology and effects on patient outcome. Curr Psychiatry Rev. 2010;6:1–10.
pubmed: 24812548
pmcid: 4011659
doi: 10.2174/157340010790596571
Baca-Garcia E, Perez-Rodriguez MM, Basurte-Villamor I, Fernandez del Moral AL, Jimenez-Arriero MA, Gonzalez de Rivera JL, et al. Diagnostic stability of psychiatric disorders in clinical practice. Br J Psychiatry. 2007;190:210–6.
pubmed: 17329740
doi: 10.1192/bjp.bp.106.024026
Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007;356:1711–22.
pubmed: 17392295
doi: 10.1056/NEJMoa064135
Terao T, Ishii N, Hirakawa H, Aoshima E. Is the bell-shaped dose-response curve of the selective serotonin reuptake inhibitor due to 5-HT1A auto-receptors? Med Hypotheses. 2020;140:109681.
pubmed: 32208294
doi: 10.1016/j.mehy.2020.109681
O’Dwyer AM, Marks I. Obsessive-compulsive disorder and delusions revisited. Br J Psychiatry. 2000;176:281–4.
pubmed: 10755077
doi: 10.1192/bjp.176.3.281
King BH, Lord C. Is schizophrenia on the autism spectrum? Brain Res. 2011;1380:34–41.
pubmed: 21078305
doi: 10.1016/j.brainres.2010.11.031
Angst J, Gamma A, Benazzi F, Ajdacic V, Eich D, Rossler W. Toward a re-definition of subthreshold bipolarity: epidemiology and proposed criteria for bipolar-II, minor bipolar disorders and hypomania. J Affect Disord. 2003;73:133–46.
pubmed: 12507746
doi: 10.1016/S0165-0327(02)00322-1
Smith DJ, Griffiths E, Kelly M, Hood K, Craddock N, Simpson SA. Unrecognised bipolar disorder in primary care patients with depression. Br J Psychiatry. 2011;199:49–56.
pubmed: 21292927
doi: 10.1192/bjp.bp.110.083840
Rasmussen SA, Eisen JL, Pato MT. Current issues in the pharmacologic management of obsessive compulsive disorder. J Clin Psychiatry. 1993;54:4–9.
Essock SM, Hargreaves WA, Dohm FA, Goethe J, Carver L, Hipshman L. Clozapine eligibility among state hospital patients. Schizophr Bull. 1996;22:15–25.
pubmed: 8685657
doi: 10.1093/schbul/22.1.15
Wimberley T, Stovring H, Sorensen HJ, Horsdal HT, MacCabe JH, Gasse C. Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study. Lancet Psychiatry. 2016;3:358–66.
pubmed: 26922475
doi: 10.1016/S2215-0366(15)00575-1
Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:1905–17.
pubmed: 17074942
doi: 10.1176/ajp.2006.163.11.1905
Souery D, Oswald P, Massat I, Bailer U, Bollen J, Demyttenaere K, et al. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry. 2007;68:1062–70.
pubmed: 17685743
doi: 10.4088/JCP.v68n0713
Rizvi SJ, Grima E, Tan M, Rotzinger S, Lin P, McIntyre RS, et al. Treatment-resistant depression in primary care across Canada. Can J Psychiatry. 2014;59:349–57.
pubmed: 25007419
pmcid: 4086317
doi: 10.1177/070674371405900702
Kennedy JL, Altar CA, Taylor DL, Degtiar I, Hornberger JC. The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int Clin Psychopharmacol. 2014;29:63–76.
pubmed: 23995856
doi: 10.1097/YIC.0b013e32836508e6
Corey-Lisle PK, Birnbaum HG, Greenberg PE, Marynchenko MB, Claxton AJ. Identification of a claims data “signature” and economic consequences for treatment-resistant depression. J Clin Psychiatry. 2002;63:717–26.
pubmed: 12197453
doi: 10.4088/JCP.v63n0810
Crown WH, Finkelstein S, Berndt ER, Ling D, Poret AW, Rush AJ, et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry. 2002;63:963–71.
pubmed: 12444808
doi: 10.4088/JCP.v63n1102
Reich D, Nalls MA, Kao WHL, Akylbekova EL, Tandon A, Patterson N et al. Reduced neutrophil count in people of African descent is due to a regulatory variant in the duffy antigen receptor for chemokines gene. PLoS Genet. 2009;5:e1000360.
Iasevoli F, Giordano S, Balletta R, Latte G, Formato MV, Prinzivalli E et al. Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2016;65,34–48.
Mrazek DA, Hornberger JC, Altar CA, Degtiar I. A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996–2013. Psychiatr Serv. 2014;65:977–87.
pubmed: 24789696
doi: 10.1176/appi.ps.201300059
Bergfeld IO, Mantione M, Figee M, Schuurman PR, Lok A, Denys D. Treatment-resistant depression and suicidality. J Affect Disord. 2018;235:362–7.
pubmed: 29665520
doi: 10.1016/j.jad.2018.04.016
Potkin SG, Kane JM, Correll CU, Lindenmayer JP, Agid O, Marder SR, et al. The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. NPJ Schizophr. 2020;6:1.
pubmed: 31911624
pmcid: 6946650
doi: 10.1038/s41537-019-0090-z
Trivedi MH, Hollander E, Nutt D, Blier P. Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression. J Clin Psychiatry. 2008;69:246–58.
pubmed: 18363453
doi: 10.4088/JCP.v69n0211
Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology. 2012;62:63–77.
pubmed: 21827775
doi: 10.1016/j.neuropharm.2011.07.036
Coplan JD, Gopinath S, Abdallah CG, Berry BR. A neurobiological hypothesis of treatment-resistant depression - mechanisms for selective serotonin reuptake inhibitor non-efficacy. Front Behav Neurosci. 2014;8:189.
pubmed: 24904340
pmcid: 4033019
doi: 10.3389/fnbeh.2014.00189
Lerner V. High-dose olanzapine for treatment-refractory schizophrenia. Clin Neuropharmacol. 2003;26:58–61.
pubmed: 12671523
doi: 10.1097/00002826-200303000-00003
Poirier MF, Boyer P. Venlafaxine and paroxetine in treatment-resistant depression—double-blind, randomised comparison. Br J Psychiatry. 1999;175:12–16.
pubmed: 10621762
doi: 10.1192/bjp.175.1.12
Adli M, Baethge C, Heinz A, Langlitz N, Bauer M. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci. 2005;255:387–400.
pubmed: 15868067
doi: 10.1007/s00406-005-0579-5
Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000;157:514–20.
pubmed: 10739409
doi: 10.1176/appi.ajp.157.4.514
Lanzenberger R, Kranz GS, Haeusler D, Akimova E, Savli M, Hahn A, et al. Prediction of SSRI treatment response in major depression based on serotonin transporter interplay between median raphe nucleus and projection areas. Neuroimage. 2012;63:874–81.
pubmed: 22828162
doi: 10.1016/j.neuroimage.2012.07.023
Demjaha A, Murray RM, McGuire PK, Kapur S, Howes OD. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry. 2012;169:1203–10.
pubmed: 23034655
doi: 10.1176/appi.ajp.2012.12010144
Howes OD, Kapur S. A neurobiological hypothesis for the classification of schizophrenia: type A (hyperdopaminergic) and type B (normodopaminergic). Br J Psychiatry. 2014;205:1–3.
pubmed: 24986384
doi: 10.1192/bjp.bp.113.138578
Duman RS, Aghajanian GK, Sanacora G, Krystal JH. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med. 2016;22:238–49.
pubmed: 26937618
pmcid: 5405628
doi: 10.1038/nm.4050
Demjaha A, Egerton A, Murray RM, Kapur S, Howes OD, Stone JM, et al. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol Psychiatry. 2014;75:e11–13.
pubmed: 23890739
doi: 10.1016/j.biopsych.2013.06.011
Pillinger T, Rogdaki M, McCutcheon RA, Hathway P, Egerton A, Howes OD. Altered glutamatergic response and functional connectivity in treatment resistant schizophrenia: the effect of riluzole and therapeutic implications. Psychopharmacology. 2019;236:1985–97.
pubmed: 30820633
pmcid: 6642056
doi: 10.1007/s00213-019-5188-5
Potkin SG, Kane JM, Correll CU, Lindenmayer JP, Agid O, Marder SR, et al. The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. Focus. 2020;18:456–65.
pubmed: 33343259
pmcid: 7725153
doi: 10.1176/appi.focus.18309
Howes OD, McCutcheon R. Inflammation and the neural diathesis-stress hypothesis of schizophrenia: a reconceptualization. Transl Psychiatry. 2017;7:e1024.
pubmed: 28170004
pmcid: 5438023
doi: 10.1038/tp.2016.278
Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014;511:421–7.
Marques TR, Ashok AH, Pillinger T, Veronese M, Turkheimer FE, Dazzan P et al. Neuroinflammation in schizophrenia: meta-analysis of in vivo microglial imaging studies. Psychol Med. 2018;49:1–11.
Pillinger T, D’Ambrosio E, McCutcheon R, Howes OD. Is psychosis a multisystem disorder? A meta-review of central nervous system, immune, cardiometabolic, and endocrine alterations in first-episode psychosis and perspective on potential models. Mol Psychiatry. 2018;24:776–94.
Pillinger T, Osimo EF, Brugger S, Mondelli V, McCutcheon RA, Howes OD. A meta-analysis of immune parameters, variability, and assessment of modal distribution in psychosis and test of the immune subgroup hypothesis. Schizophr Bull. 2018;45:1120–33.
Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9:46–56.
pubmed: 18073775
pmcid: 2919277
doi: 10.1038/nrn2297
Benros ME, Waltoft BL, Nordentoft M, Ostergaard SD, Eaton WW, Krogh J, et al. Autoimmune diseases and severe infections as risk factors for mood disorders a nationwide study. Jama Psychiatry. 2013;70:812–20.
pubmed: 23760347
doi: 10.1001/jamapsychiatry.2013.1111
Mondelli V, Ciufolini S, Murri MB, Bonaccorso S, Di Forti M, Giordano A, et al. Cortisol and inflammatory biomarkers predict poor treatment response in first episode psychosis. Schizophr. Bull. 2015;41:1162–70.
pubmed: 25829375
pmcid: 4535637
doi: 10.1093/schbul/sbv028
Fillman SG, Weickert TW, Lenroot RK, Catts SV, Bruggemann JM, Catts VS, et al. Elevated peripheral cytokines characterize a subgroup of people with schizophrenia displaying poor verbal fluency and reduced Broca’s area volume. Mol Psychiatry. 2016;21:1090–8.
pubmed: 26194183
doi: 10.1038/mp.2015.90
Osimo EF, Pillinger T, Rodriguez IM, Khandaker GM, Pariante CM, Howes OD. Inflammatory markers in depression: a meta-analysis of mean differences and variability in 5166 patients and 5,083 controls. Brain Behav Immun. 2020;87:901–9.
pubmed: 32113908
pmcid: 7327519
doi: 10.1016/j.bbi.2020.02.010
Chamberlain SR, Cavanagh J, de Boer P, Mondelli V, Jones DNC, Drevets WC, et al. Treatment-resistant depression and peripheral C-reactive protein. Br J Psychiatry. 2019;214:11–19.
pubmed: 29764522
pmcid: 6124647
doi: 10.1192/bjp.2018.66
Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70:31–41.
pubmed: 22945416
pmcid: 4015348
doi: 10.1001/2013.jamapsychiatry.4
McIntyre RS, Subramaniapillai M, Lee Y, Pan Z, Carmona NE, Shekotikhina M et al. Efficacy of adjunctive infliximab vs placebo in the treatment of adults with bipolar I/II depression: a randomized clinical trial. JAMA Psychiatry 2019;76:783–90.
Steiner J, Bogerts B, Sarnyai Z, Walter M, Gos T, Bernstein HG, et al. Bridging the gap between the immune and glutamate hypotheses of schizophrenia and major depression: Potential role of glial NMDA receptor modulators and impaired blood-brain barrier integrity. World J Biol Psychiatry. 2012;13:482–92.
pubmed: 21707463
doi: 10.3109/15622975.2011.583941
Mueller N, Schwarz MJ. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry. 2007;12:988–1000.
doi: 10.1038/sj.mp.4002006
Muller N, Weidinger E, Leitner B, Schwarz MJ. The role of inflammation in schizophrenia. Front Neurosci. 2015;9:372.
Claghorn JL, Abuzzahab FS, Wang R, Larson C, Gelenberg AJ, Klerman GL, et al. The current status of clozapine. Psychopharmacol Bull. 1983;19:138–40.
Yilmaz Z, Zai CC, Hwang R, Mann S, Arenovich T, Remington G, et al. Antipsychotics, dopamine D(2) receptor occupancy and clinical improvement in schizophrenia: a meta-analysis. Schizophr Res. 2012;140:214–20.
pubmed: 22795368
doi: 10.1016/j.schres.2012.06.027
Kaar SJ, Natesan S, McCutcheon R, Howes OD Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. Neuropharmacology 2019;172:107704.
Jauhar S, Morrison P. Esketamine for treatment resistant depression. BMJ. 2019;366:l5572.
pubmed: 31548292
doi: 10.1136/bmj.l5572
Kavalali ET, Monteggia LM. Synaptic mechanisms underlying rapid antidepressant action of ketamine. Am J Psychiatry. 2012;169:1150–6.
pubmed: 23534055
doi: 10.1176/appi.ajp.2012.12040531
Kokkinou M, Ashok AH, Howes OD. The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders. Mol Psychiatry. 2018;23:59–69.
pubmed: 28972576
doi: 10.1038/mp.2017.190
Thase ME, Corya SA, Osuntokun O, Case M, Henley DB, Sanger TM, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry. 2007;68:224–36.
pubmed: 17335320
doi: 10.4088/JCP.v68n0207
Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 2001;158:131–4.
pubmed: 11136647
doi: 10.1176/appi.ajp.158.1.131
Shelton RC, Williamson DJ, Corya SA, Sanger TM, Van Campen LE, Case M, et al. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry. 2005;66:1289–97.
pubmed: 16259543
doi: 10.4088/JCP.v66n1012
Thase ME, Trivedi MH, Nelson JC, Fava M, Swanink R, Tran QV, et al. Examining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studies. Prim Care Comp J Clin Psychiatry. 2008;10:440–7.
doi: 10.4088/PCC.v10n0603
Nierenberg AA, Feighner JP, Rudolph R, Cole JO, Sullivan J. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol. 1994;14:419–423.
pubmed: 7884023
doi: 10.1097/00004714-199412000-00008
Owens MJ, Krulewicz S, Simon JS, Sheehan DV, Thase ME, Carpenter DJ, et al. Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine. Neuropsychopharmacology. 2008;33:3201–3212.
pubmed: 18418363
doi: 10.1038/npp.2008.47
FDA. U.S. Food & Drug Administration. Repetitive Transcranial Magnetic Stimulation (rTMS) Systems—Class II Special Controls Guidance for Industry and FDA Staff. https://www.fda.gov/medical-devices/guidance-documents-medical-devices-and-radiation-emitting-products/repetitive-transcranial-magnetic-stimulation-rtms-systems-class-ii-special-controls-guidance#1 ; 2011.
Fosse R, Read J. Electroconvulsive treatment: hypotheses about mechanisms of action. Front Psychiatry. 2013;4:94.
pubmed: 23986724
pmcid: 3753611
doi: 10.3389/fpsyt.2013.00094
Jauhar S, Nour MM, Veronese M, Rogdaki M, Bonoldi I, Azis M, et al. A test of the transdiagnostic dopamine hypothesis of psychosis using positron emission tomographic imaging in bipolar affective disorder and schizophrenia. JAMA Psychiatry. 2017;74:1206–1213.
pubmed: 29049482
pmcid: 6059355
doi: 10.1001/jamapsychiatry.2017.2943
Wimberley T, Gasse C, Meier SM, Agerbo E, MacCabe JH, Horsdal HT. Polygenic risk score for schizophrenia and treatment-resistant schizophrenia. Schizophr Bull. 2017;43:1064–1069.
pubmed: 28184875
pmcid: 5581885
doi: 10.1093/schbul/sbx007
Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161:1–56.
pubmed: 15000267
Barnes TRE, Psychopharmacology BA. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2011;25:567–620.
pubmed: 21292923
doi: 10.1177/0269881110391123
IPAP. International Psychopharmacology Algorithm Project ( www.ipap.org ): Schizophrenia Algorithm Flowchart. 2019.
Taylor D, Barnes T, Young A. The maudsley prescribing guidelines in psychiatry 13th edn. Wiley Blackwell; 2018.
Verma S, Chan LL, Chee KS, Chen H, Chin SA, Chong SA, et al. Ministry of Health Clinical Practice Guidelines: Schizophrenia. Singap Med J. 2011;52:521–525.
NICE. Psychosis and schizophrenia in adults: prevention and management, CG178. 2014.
McGorry P, Killackey E, Lambert T, Lambert M, Jackson H, Codyre D, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust NZ J Psychiatry. 2005;39:1–30.
doi: 10.1080/j.1440-1614.2005.01516.x
Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Moller HJ, et al. World Federation of Societies of Biological Psychiatry (WFSBP)—Guidelines for biological treatment of schizophrenia, part 1: Acute treatment of schizophrenia. World J Biol Psychiatry. 2005;6:132–91.
pubmed: 16173147
doi: 10.1080/15622970510030090
Practice guideline for major depressive disorder in adults. American Psychiatric Association. Am J Psychiatry. 1993;150:1–26.
Gelenberg A, Freeman MP, Markowitz J, Rosenbaum JF, Thase M, Madhukar T et al. Practice guideline for the treatment of patients with major depressive disorder, 3rd edn. American Psychiatric Association; 2010.
Cleare A, Pariante CM, Young AH, Anderson IM, Christmas D, Cowen PJ, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2015;29:459–525.
pubmed: 25969470
doi: 10.1177/0269881115581093
Kennedy SH, Lam RW, McIntyre RS, Tourjman SV, Bhat V, Blier P, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the management of adults with major depressive disorder: section 3. pharmacological treatments. Can J Psychiatry. 2016;61:540–60.
pubmed: 27486148
pmcid: 4994790
doi: 10.1177/0706743716659417
Milev RV, Giacobbe P, Kennedy SH, Blumberger DM, Daskalakis ZJ, Downar J, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the management of adults with major depressive disorder: section 4. neurostimulation treatments. Can J Psychiatry. 2016;61:561–75.
pubmed: 27486154
pmcid: 4994792
doi: 10.1177/0706743716660033
Schosser A, Serretti A, Souery D, Mendlewicz J, Zohar J, Montgomery S, et al. European Group for the Study of Resistant Depression (GSRD)—Where have we gone so far: review of clinical and genetic findings. Eur Neuropsychopharmacol. 2012;22:453–68.
pubmed: 22464339
doi: 10.1016/j.euroneuro.2012.02.006
Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.
pubmed: 14399272
pmcid: 495331
doi: 10.1136/jnnp.23.1.56
McAllister-Williams RH, Christmas DMB, Cleare AJ, Currie A, Gledhill J, Insole L, et al. Multiple-therapy-resistant major depressive disorder: a clinically important concept. Br J Psychiatry. 2018;212:274–8.
pubmed: 30517072
doi: 10.1192/bjp.2017.33
Chua HC, Chan LL, Chee KS, Chen YH, Chin SA, Chua PLW, et al. Ministry of Health Clinical Practice Guidelines: depression. Singap Med J. 2012;53:137–43.
NICE Depression in adults: recognition and management. National Institute for Clinical Excellence. CG90 (updated April 2018). 2009.
Malhi GS, Bassett D, Boyce P, Bryant R, Fitzgerald PB, Fritz K, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2015;49:1087–206.
pubmed: 26643054
doi: 10.1177/0004867415617657
Bauer M, Severus E, Moller HJ, Young AH. Disorders WTFoUD. Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines. Int J Psychiatry Clin Pr. 2017;21:166–76.
doi: 10.1080/13651501.2017.1306082
Hidalgo-Mazzei D, Berk M, Cipriani A, Cleare AJ, Di Florio A, Dietch D, et al. Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition. Br J Psychiatry. 2019;214:27–35.
pubmed: 30520709
doi: 10.1192/bjp.2018.257
Geller DA & March J. Practice parameter for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 2012;51:98–113.
Pallanti S, Hollander E, Bienstock C, Koran L, Leckman J, Marazziti D, et al. Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol. 2002;5:181–91.
pubmed: 12135542
doi: 10.1017/S1461145702002900
Mataix-Cols D, Fernandez de la Cruz L, Nordsletten AE, Lenhard F, Isomura K, Simpson HB. Towards an international expert consensus for defining treatment response, remission, recovery and relapse in obsessive-compulsive disorder. World Psychiatry. 2016;15:80.
pubmed: 26833615
pmcid: 4780290
doi: 10.1002/wps.20299
Hollister LE. Monitoring tricyclic antidepressant plasma concentrations. JAMA. 1979;241:2530–3.
pubmed: 439339
doi: 10.1001/jama.1979.03290490036022
Nikisch G, Baumann P, Oneda B, Kiessling B, Weisser H, Mathe AA, et al. Cytochrome P450 and ABCB1 genetics: association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study. J Psychopharmacol. 2011;25:896–907.
pubmed: 21148022
doi: 10.1177/0269881110389208
Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008;57:203–9.
pubmed: 18215618
doi: 10.1016/j.neuron.2007.11.017
Perera V, Gross AS, Polasek TM, Qin Y, Rao G, Forrest A, et al. Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia. Expert Opin Drug Met. 2013;9:1115–37.
doi: 10.1517/17425255.2013.795540
Baumann P, Broly F, Kosel M, Eap CB. Ultrarapid metabolism of clomipramine in a therapy-resistant depressive patient, as confirmed by CYP2 D6 genotyping. Pharmacopsychiatry. 1998;31:72–72.
pubmed: 9562213
doi: 10.1055/s-2007-979303
Skogh E, Reis M, Dahl ML, Lundmark J, Bengtsson F. Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting. Ther Drug Monit. 2002;24:518–26.
pubmed: 12142637
doi: 10.1097/00007691-200208000-00010
Leinonen E, Lillsunde P, Laukkanen V, Ylitalo P. Effects of carbamazepine on serum antidepressant concentrations in psychiatric-patients. J Clin Psychopharmacol. 1991;11:313–8.
pubmed: 1765574
doi: 10.1097/00004714-199110000-00007
Fabbri C, Tansey KE, Perlis RH, Hauser J, Henigsberg N, Maier W, et al. Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: meta-analysis of data from genome-wide association studies. Eur Neuropsychopharmacol. 2018;28:945–54.
pubmed: 30135031
doi: 10.1016/j.euroneuro.2018.05.009
Wagner E, McMahon L, Falkai P, Hasan A, Siskind D. Impact of smoking behavior on clozapine blood levels—a systematic review and meta-analysis. Acta Psychiatr Scand. 2020;142:456–66.
pubmed: 32869278
doi: 10.1111/acps.13228
Augustin M, Schoretsanitis G, Hiemke C, Grunder G, Haen E, Paulzen M. Differences in duloxetine dosing strategies in smoking and nonsmoking patients: therapeutic drug monitoring uncovers the impact on drug metabolism. J Clin Psychiatry. 2018;79:5.
Patel MX, Bowskill S, Couchman L, Lay V, Taylor D, Spencer EP, et al. Plasma olanzapine in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1999–2009. J Clin Psychopharmacol. 2011;31:411–7.
pubmed: 21694620
doi: 10.1097/JCP.0b013e318221b408
Kokras N, Dalla C, Papadopoulou-Daifoti Z. Sex differences in pharmacokinetics of antidepressants. Expert Opin Drug Met. 2011;7:213–26.
doi: 10.1517/17425255.2011.544250